![]() Past performance is a poor indicator of future performance. Price target upside according to sell-side analysts. The price boost on the next news is forecasted to be 3.79 whereas the daily expected return is currently at -0.77. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. BEEMs dividend yield, history, payout ratio, proprietary DARS rating & much more. ![]() The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Average price target from 8 ratings: 26.00 Average score: Sell Under Hold Over Buy Full Ratings Open 9.35 Previous Close- YTD Change -44.48 12 Month Change -47.05 Day Range9.19 - 9.80 52. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. Is not operated by a broker, a dealer, or a registered investment adviser. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301. The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. ![]() develops and commercializes DNA base editing technologies for the treatment of human disease.
0 Comments
Leave a Reply. |